Introduction
ADCTA, Autologous Dendritic Cell/Tumor Antigen
Has safety, efficacy and almost no effect sides clinical trial proven outcome.
ADCTAK, Dendritic Ccell – Cytokine Iinduced Killer Cell/Tumor Antigen
Is based on ADCTA's outcome as well as CIK killer's character makes it powerful at the start of the treatment cycle.
Features / strengths
CLINICAL TRIAL PROVEN OUTCOME:
SAFETY !
EFFICACY !
GOOD LIVING QUALITY !
Specification in detail
A cycle of treatment
10 times scheduled injections/around 6 to 8 months
